Sunshine Biopharma Inc (SBFM)
0.8622
-0.03
(-3.39%)
USD |
NASDAQ |
May 13, 16:00
0.851
-0.01
(-1.30%)
After-Hours: 19:12
Sunshine Biopharma Cash from Financing (TTM): 3.426M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.426M |
| September 30, 2023 | 1.360M |
| June 30, 2023 | 1.423M |
| March 31, 2023 | 26.49M |
| December 31, 2022 | 39.47M |
| September 30, 2022 | 41.54M |
| June 30, 2022 | 42.81M |
| March 31, 2022 | 14.24M |
| December 31, 2021 | 2.905M |
| September 30, 2021 | 3.853M |
| June 30, 2021 | 3.102M |
| March 31, 2021 | 2.710M |
| December 31, 2020 | 1.608M |
| September 30, 2020 | 0.7738M |
| June 30, 2020 | 0.3818M |
| March 31, 2020 | 0.2276M |
| December 31, 2019 | 0.4423M |
| September 30, 2019 | 0.5249M |
| June 30, 2019 | 0.4839M |
| March 31, 2019 | 0.4937M |
| December 31, 2018 | 0.5276M |
| September 30, 2018 | 0.569M |
| June 30, 2018 | 0.6582M |
| March 31, 2018 | 0.853M |
| December 31, 2017 | 0.6707M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.5259M |
| June 30, 2017 | 0.3562M |
| March 31, 2017 | 0.2267M |
| December 31, 2016 | 0.3246M |
| September 30, 2016 | 1.148M |
| June 30, 2016 | 1.211M |
| March 31, 2016 | 1.444M |
| December 31, 2015 | 1.399M |
| September 30, 2015 | 0.7228M |
| June 30, 2015 | 0.8025M |
| March 31, 2015 | 0.6391M |
| December 31, 2014 | 0.6508M |
| September 30, 2014 | 0.4335M |
| June 30, 2014 | 0.28M |
| March 31, 2014 | 0.13M |
| December 31, 2013 | 0.463M |
| September 30, 2013 | 0.513M |
| June 30, 2013 | 0.8655M |
| March 31, 2013 | 0.9155M |
| December 31, 2012 | 0.465M |
| September 30, 2012 | 0.415M |
| June 30, 2012 | 0.2581M |
| March 31, 2012 | 0.2081M |
| December 31, 2011 | 0.1956M |
| September 30, 2011 | 0.4942M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.2276M
Minimum
Mar 2020
42.81M
Maximum
Jun 2022
9.882M
Average
2.710M
Median
Mar 2021
Cash from Financing (TTM) Benchmarks
| Lexaria Bioscience Corp | 6.862M |
| Acasti Pharma Inc | 7.359M |
| Aurinia Pharmaceuticals Inc | -5.13M |
| Edesa Biotech Inc | 2.224M |
| Xenon Pharmaceuticals Inc | 353.52M |